Peptide Center / TB-500
Not FDA-approvedTB-500: evidence, status & safety
TB-500 is commonly described as a thymosin beta-4 fragment and sold for recovery or tissue repair. It is not an FDA-approved human drug.
Clinical Snapshot
What patients should know first
| Commonly discussed for | Soft-tissue healing, flexibility, endurance and faster recovery. |
| What efficacy data show | FDA states it has not identified human exposure data for drug products containing the marketed thymosin beta-4 fragment known as TB-500. Research involving full-length thymosin beta-4 cannot automatically validate fragment products. |
| Approval boundary | The identity, sequence, dose and manufacturing quality of online products may not match substances studied in laboratories. |
| Safety context | FDA identifies potential immunogenicity, aggregation and peptide-related impurity concerns and lacks sufficient information to know whether the fragment would cause harm in humans. |
Interpretation
Do not confuse a molecule with a verified medication
The name of an active ingredient does not verify the product in a vial. FDA approval, when it exists, applies to a specific product and indication. A compounded version is not FDA-approved, and a research-labeled product is not approved for human use.
Clinical supervision should include diagnosis, contraindication and interaction review, realistic outcome discussion, a valid prescription, traceable sourcing and follow-up. It cannot make an anonymous or counterfeit product safe.
Questions to ask
- Is there an FDA-approved product for my exact condition?
- What human outcome—not only biomarker—supports this use?
- What are the important contraindications and stopping rules?
- Which licensed pharmacy will dispense the prescription?
- How will response and adverse effects be monitored?
Primary Sources
Verify the evidence
Evidence Before TreatmentKnow the status.
Know the status.
Verify the source.
This guide is educational and cannot determine whether TB-500 is appropriate for you.